Dyne Therapeutics (NASDAQ:DYN) Sets New 12-Month Low – Here’s What Happened

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s stock price hit a new 52-week low on Tuesday . The stock traded as low as $11.33 and last traded at $11.50, with a volume of 1605555 shares. The stock had previously closed at $12.40.

Wall Street Analyst Weigh In

Several research firms recently commented on DYN. Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. HC Wainwright reduced their price target on shares of Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Piper Sandler reduced their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Finally, Robert W. Baird began coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $48.85.

Dyne Therapeutics Trading Up 2.7 %

The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -3.47 and a beta of 1.11. The stock’s 50 day moving average is $15.10 and its 200 day moving average is $25.73.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now directly owns 199,087 shares of the company’s stock, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 20.77% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently modified their holdings of the company. FMR LLC boosted its stake in shares of Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after purchasing an additional 3,707,734 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Dyne Therapeutics by 8.3% during the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company’s stock worth $173,808,000 after purchasing an additional 566,146 shares during the last quarter. RTW Investments LP boosted its stake in shares of Dyne Therapeutics by 6.8% during the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after purchasing an additional 431,503 shares during the last quarter. RA Capital Management L.P. boosted its stake in shares of Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after purchasing an additional 331,940 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Dyne Therapeutics by 13.8% during the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after purchasing an additional 440,890 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.